Molbio Diagnostics IPO: dates, price band, lot size and GMP
Molbio Diagnostics IPO listed on 17 Aug at ₹980 (NSE, BSE). Issue dates 10 – 12 Aug 2026, price band ₹807, lot 18 shares. The shares now trade on the exchange; any pre-IPO price on this site is historical.
Updated 6 Oct 2026, 14:11 IST. Dated dealer references.
BuyUnlistedShares tracks 197 IPOs on its calendar; the Molbio Diagnostics IPO has a price band of ₹807, a lot of 18 shares and no grey-market premium reported yet as of 06 Oct 2026.
Key details
| Board | Mainboard |
|---|---|
| Issue dates | 10 – 12 Aug 2026 |
| Price band | ₹807 |
| Lot size | 18 shares |
| Issue size | ₹939.70 Cr |
| Fresh issue | ₹200 Cr |
| Offer for sale | ₹739.7 Cr |
| Subscription | 70.27x |
| Registrar | Kfin Technologies Ltd. |
| Lead managers | Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. |
| Status | Listed |
Timeline
- Issue opens: 10 Aug
- Issue closes: 12 Aug
- Allotment: 13 Aug
- Refunds: 14 Aug
- Demat credit: 14 Aug
- Listing: 17 Aug
Live subscription
| Category | Subscribed |
|---|---|
| QIB | 186.39x |
| NII | 49.8x |
| sNII | 47.76x |
| bNII | 50.82x |
| Retail | 12.97x |
| Total | 70.27x |
Last updated 12 Aug 2026, 6:53 PM IST.
Issue details
| Face value | ₹1 |
|---|---|
| Issue type | Book Build Issue |
| Listing at | NSE, BSE |
| Market cap at the upper band | ₹9,299.87 Cr |
| P/E (pre-issue) | 55.43x |
| P/E (post-issue) | 56.67x |
| Fresh issue (shares) | 24,80,246 |
| Offer for sale (shares) | 91,66,000 |
| Total shares offered | 1,16,46,246 |
| Promoter holding pre-issue | 44.89% |
| Promoter holding post-issue | 41.29% |
| Promoters | Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Exxora Trading LLP |
| Lead managers | Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. |
| Registrar phone | 040-79615565 |
| Registrar email | molbio.ipo@kfintech.com |
| Company website | molbiodiagnostics.com |
| Anchor bid date | 7 Aug 2026 |
| Anchor lock-in ends (50%) | 11 Sep 2026 |
| Anchor lock-in ends (remaining) | 10 Nov 2026 |
Lot sizes by investor category
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (minimum) | 1 | 18 | ₹14,526 |
| Retail (maximum) | 14 | 252 | ₹2,03,364 |
| sNII (minimum) | 14 | 252 | ₹2,03,364 |
| bNII (minimum) | 69 | 1,242 | ₹10,02,294 |
Reservation
| Category | Share of issue | Shares offered | Basis |
|---|---|---|---|
| Anchor Investor | 29.9% | 34,87,717 | |
| QIB | 20% | 23,25,146 | Not more than 50% of the Net Offer |
| NII (HNI) | 15% | 17,43,859 | Not less than 15% of the Net Offer |
| sNII | 5% | 5,81,286 | |
| bNII | 10% | 11,62,573 | |
| Retail | 34.9% | 40,69,004 | Not less than 35% of the Net Offer |
| Employee | 0.2% | 20,520 |
Subscription by day
| Day | QIB | NII | sHNI | bHNI | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 · 10 Aug | 1.00x | 0.73x | 0.80x | 0.70x | 0.77x | 0.83x |
| Day 2 · 11 Aug | 1.39x | 5.13x | 7.02x | 4.31x | 3.19x | 3.08x |
| Day 3 · 12 Aug | 186.39x | 49.80x | 47.76x | 50.82x | 12.97x | 70.27x |
Key ratios as of 31 Mar 2025
| EPS (pre-issue) | ₹14.56 |
|---|---|
| EPS (post-issue) | ₹14.24 |
| P/E (pre-issue) | 55.43x |
| P/E (post-issue) | 56.67x |
| RoNW | 15.23% |
| RoCE | 20.98% |
| RoE | 16.2% |
| PAT margin | 13.48% |
| EBITDA margin | 24.97% |
| Price / book | 9.55x |
| NAV per share | ₹84.51 |
| Market cap (upper band) | ₹9,299.87 Cr |
Financials (₹ Cr)
| Metric | FY26 | FY25 | FY24 | FY26 vs FY25 |
|---|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 | +47% |
| Total Income | 1,455.17 | 1,027.94 | 840.66 | +41.6% |
| Profit After Tax | 164.14 | 138.58 | 83.54 | +18.4% |
| EBITDA | 328.24 | 256.64 | 185.09 | +27.9% |
| NET Worth | 1,144.68 | 952.95 | 807.94 | +20.1% |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 | +15.9% |
| Total Borrowing | 412.64 | 123.16 | 174.58 | +235% |
About Molbio Diagnostics
Molbio Diagnostics Limited is a healthcare technology company specializing in point-of-care (POC) diagnostic solutions designed to enable fast, accurate, and affordable disease detection. The company focuses on both infectious and non-communicable diseases, offering innovative diagnostic technologies that can be deployed in hospitals, laboratories, and remote healthcare settings. Its flagship innovation, the “Truenat” platform, is a portable real-time polymerase chain reaction (PCR) testing system that enables decentralized molecular diagnostics with results available in less than an hour.
Designed for use even in resource-constrained environments, the platform has been patented in more than 100 countries as of March 31, 2025. Truenat supports testing for over 30 diseases through 42 diagnostic assays , covering conditions such as tuberculosis (TB), COVID-19, Hepatitis B, Hepatitis C, HIV, and Human Papillomavirus (HPV). The Truenat TB test is among the limited number of rapid molecular diagnostic tests endorsed by the World Health Organization (WHO) for the initial detection of tuberculosis and rifampicin resistance. Beyond molecular diagnostics, the company has expanded its healthcare solutions portfolio through strategic partnerships and group entities.
It offers radiology, digital pathology, and breast health screening technologies through its subsidiary Prognosys , associate company OptraScan , and collaboration partner UE Lifesciences , providing integrated diagnostic solutions across multiple healthcare segments. Molbio operates a network of five manufacturing facilities across India, including two units in Goa , one in Visakhapatnam, Andhra Pradesh , and two in Bengaluru, Karnataka . These facilities manufacture diagnostic instruments, molecular test kits, and medical imaging products, including portable and mobile X-ray systems.
The company has established a strong international footprint, with operations spanning more than 80 countries supported by a network of 33 international distributors . As of March 31, 2025, it had sold over 10,000 diagnostic devices globally. Its products are supplied to public healthcare programs, hospitals, diagnostic laboratories, and healthcare institutions through both direct sales and distribution channels. Molbio generates revenue through the sale of diagnostic devices and recurring income from its proprietary test kits and consumables, creating a scalable business model supported by a growing installed base of diagnostic systems.
Objects of the issue
- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. — ₹105.54 Cr
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and — ₹72.28 Cr
- General Corporate Purposes — ₹9.47 Cr
- Issue Expenses — ₹59.54 Cr
Net proceeds: ₹246.83 Cr
Peer comparison
| Company | EPS (Basic) | EPS (Diluted) | NAV (₹ per share) | P/E (x) | RoNW (%) | Financial statements |
|---|---|---|---|---|---|---|
| Molbio Diagnostics Ltd. (issuer) | 14.77 | 14.77 | 101.51 | — | 14.55% | Restated |
| Poly Medicure Ltd | 31.79 | 31.75 | 306.45 | 52.61x | 10.37% | Consolidated |
| Dr. Lal Pathlabs Ltd | 30.24 | 30.2 | 145 | 62.2x | 20.78% | Consolidated |
| Metropolis Healthcare Ltd | 9.19 | 9.19 | 72.98 | 63.72x | 12.56% | Consolidated |
| Vijaya Diagnostic Centre Ltd | 16.81 | 16.79 | 93.02 | 81.02x | 18.07% | Consolidated |
Source: All the financial information for listed industry peers mentioned above is on a consolidated basis (unless otherwise available only on standalone basis) and is sourced from the annual reports / other publicly available information as available on the website of peers for the financial year ended March 31, 2026. *Financial information of the Company has been derived as at or for the year ended March 31, 2026.
Offer documents: DRHP (PDF) · RHP (PDF)
Track this issue
- Molbio Diagnostics IPO GMP today and trend
- Molbio Diagnostics IPO subscription status, day by day
- Molbio Diagnostics IPO allotment status and how to check
Frequently asked questions
When does the Molbio Diagnostics IPO open and close?
The issue is scheduled for 10 – 12 Aug 2026.
What is the Molbio Diagnostics IPO price band?
The price band is ₹807 per share with a lot size of 18 shares.
How big is the Molbio Diagnostics IPO?
The total issue size is ₹939.70 Cr, of which ₹200 Cr is a fresh issue and ₹739.7 Cr an offer for sale.
When will Molbio Diagnostics list?
The tentative listing date is 17 Aug on the main board.
How do I apply for the Molbio Diagnostics IPO?
Apply through your broker or bank using ASBA or UPI within the issue window; the amount stays blocked in your account until allotment. BuyUnlistedShares does not take applications; it tracks the issue and the unlisted price before it.
Sources
- Draft red herring prospectus (DRHP), Molbio Diagnostics · as filed with SEBI · sebi.gov.in
- Red herring prospectus (RHP), Molbio Diagnostics · as filed · sebi.gov.in
- Registrar allotment page, Kfin Technologies Ltd. · allotment 13 Aug · ipostatus.kfintech.com
- NSE public issues page · listing 17 Aug · nseindia.com
- BSE public issues page · listing 17 Aug · bseindia.com
- Molbio Diagnostics company website · molbiodiagnostics.com
- BuyUnlistedShares IPO record: GMP, subscription and allotment, dated daily · GMP as of 17 Aug, 03:23 · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Molbio Diagnostics IPO”, https://buyunlistedshares.com/ipo/molbio-diagnostics-ipo, as of 06 Oct 2026.
Other IPOs on the calendar
- Paramount Syntex IPO · 30 Sep – 6 Oct 2026
- TNA Solutions IPO · 30 Sep – 6 Oct 2026
- Acme India Industries IPO · 30 Sep – 6 Oct 2026
- R.K.Fashion Accessories IPO · 5 – 7 Oct 2026
- Jio Platforms IPO · 21 – 23 Oct 2026
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk: the unlisted and pre-IPO dealing desk of Gayatri Financial Synergy, Faridabad, in the market since 2002. Reviewed by the BuyUnlistedShares desk before publishing. Data as of 06 Oct 2026.
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Ask · Community · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Part of the Gayatri Financial Synergy group (gayatrifin.com): AMFI-registered mutual fund distributor, Faridabad, since 2002.
